Videos

Ali Duffens, MD, discusses the relative effectiveness of different detection modalities in identifying breast cancer recurrences.

Dr. Tarantino provides final thoughts, highlighting unmet needs and future directions in early HER2+ breast cancer on Precision Medicine in Oncology.

Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.

Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.

Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.

Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.

Neeraj Agarwal, MD, discusses some of the unmet needs that exist in the prostate cancer space.

Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.

Mayuko Sakae, MD, discusses findings from research presented at the 2024 Multinational Association of Supportive Care in Cancer Annual Meeting on refractory pain in patients who have undergone a bone marrow transplant.

Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.

Dr Sekeres discusses when to start therapy for a patient who has lower-risk MDS with amnesia.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with imetelstat.

Dr Sekeres discusses treatment goals for a patient with lower-risk MDS.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.

Dr Sekeres discusses key takeaways for optimizing anemia management in lower-risk MDS, as well as where he sees the most significant unmet needs.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with lenalidomide.

Dr Sekeres shares his thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.

Dr Sekeres discusses the adverse event profile and AE management of imetelstat.

Oncology specialists analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic renal cell carcinoma.

Renal cell carcinoma experts examines risk stratification strategies to guide their treatment approaches for a 59-year-old woman with RCC.

Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.

A panel of renal cell carcinoma experts deliberates on the treatment approach for a 59-year-old woman diagnosed with a left renal mass.

Rohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.

Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.

Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.

Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.

Douglas Tremblay, MD, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms and their safety profiles.

Yannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Paula Rodríguez Otero, MD, PhD, discussed the findings from the minimal residual disease analysis of the PERSEUS study.

Edwin Choy, MD, PhD, discusses the mechanism of action of afamitresgene autoleucel and the recent accelerated approval from the FDA for patients with advanced synovial sarcoma.